Cyxone further strengthens the team to reinforce the development projects
Cyxone (publ.), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, today announced the recruitment of Sally Abdelmoaty as Project Manager to focus on the next step in the development of Cyxone's drug portfolio. The recruitment will strengthen Cyxone’s capabilities in non-clinical drug development. Sally Abdelmoaty will primarily focus on the T20K project but will contribute with her deep scientific knowledge to all projects.Sally Abdelmoaty holds a PhD in Pharmacology and Toxicology from Karolinska Institutet, Solna, Sweden and Faculty of Pharmacy,